Evidence map›Paper›PMID 41772418›Full record

ArticleCellular & molecular biology letters2026

Toll-like receptor 2 drives liver senescence and fibrosis in aging through gut-derived microbial signaling.

Annette Brandt, Raphaela Staltner, Anja Baumann, Katharina Burger, Julia Jelleschitz, Patricia Oliveira Prada, Annika Höhn, Florian Kopp, Jordi Mayneris-Perxachs, José Manuel Fernández-Real and 1 more

Abstract read
In one paragraph

Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Annette BrandtDepartment of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria.
Raphaela StaltnerDepartment of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria.
Anja BaumannDepartment of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria.
Katharina BurgerDepartment of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria.
Julia JelleschitzGerman Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.
Patricia Oliveira PradaDepartment of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria.
Annika HöhnGerman Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.
Florian KoppClinical Pharmacy Group, Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
Jordi Mayneris-PerxachsIntegrative Systems Medicine and Biology Group, Girona Biomedical Research Institute (IDIBGI-CERCA), Salt, Spain.
José Manuel Fernández-RealDepartment of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
Ina BergheimDepartment of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria. ina.bergheim@univie.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile the role of endotoxins from Gram-negative bacteria has been studied extensively, the contribution of Gram-positive bacterial components—particularly those activating toll-like receptor 2 (TLR2), such as lipoteichoic acid (LTA)—to liver aging, inflammation, and fibrosis remains poorly understood. Here, we investigated the role of TLR2 and its ligand LTA in liver aging by using murine models, in vitro experiments, and human samples from young and elderly individuals.

methodsTLR2 ligands were evaluated in serum samples from young (aged 21–33 years) and elderly (aged 65–77 years) healthy individuals. Markers of liver damage, senescence, and inflammation were assessed in 4- and 20-month-old male C57BL/6 and TLR2 knockout (TLR2−/−) mice. In addition, 17-month-old male C57BL/6 mice were treated either with the TLR2 inhibitor ortho-vanillin (60 mg/kg BW in drinking water) or plain water for 4 months and markers as determined above were assessed. The presence of markers of senescence was measured in J774A.1 cells and human peripheral blood mononuclear cells stimulated with LTA.

resultsIn humans and mice, aging was associated with significantly elevated circulating levels of TLR2 ligands. In aging mice, this was accompanied by increased hepatic Tlr2 mRNA expression. Strikingly, 20-month-old male TLR2−/− mice exhibited reduced markers of senescence (e.g., plasma plasminogen activator inhibitor-1 and liver p16 expression), inflammation (e.g., hepatic neutrophil infiltration, Il1b mRNA expression), and fibrosis (e.g., α-smooth muscle actin expression, Sirius Red staining), compared with age-matched wild-type controls. Similarly, in aged male C57BL/6 J mice showing first signs of impaired intestinal barrier function i.e., rising peripheral TLR2 ligand levels in plasma, treatment with the TLR2 inhibitor ortho-vanillin for 4 months attenuated the progression of liver aging as indicated by attenuated senescence, liver inflammation, and fibrosis. In vitro, stimulation of J774A.1 macrophages and human peripheral blood mononuclear cells with LTA induced the expression of senescence-associated genes p16 and p21.

conclusionsCollectively, these findings suggest that increased translocation of TLR2 ligands and subsequent activation of TLR2-dependent pathways play a critical role in age-associated liver degeneration. Targeting TLR2 signaling may therefore represent a promising therapeutic approach to mitigate hepatic aging and associated pathologies.

Indexed as

AgingLiverLiver CirrhosisToll-Like Receptor 2AdultAgedAnimalsCellular SenescenceHumansLipopolysaccharidesMaleMiceMice, Inbred C57BLMice, KnockoutSignal TransductionTeichoic AcidsLipopolysaccharideslipoteichoic acidTeichoic AcidsToll-Like Receptor 2AgingFibrosisHepatic inflammationLipoteichoic acidSenescenceTLR2

Identifiers

PMID41772418
PMCPMC13064244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.